Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 24;57(12):1293. doi: 10.3390/medicina57121293

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

(a) Changes in the central retinal thickness during individual follow-up visits—comparison of treatment results for Aflibercept and Ranibizumab. The obtained decreases in retinal thickness did not differ significantly statistically between the two groups, (p > 0.05). (b) Average change in central retinal thickness after the first and second years of treatment—comparison of treatment results for Aflibercept and Ranibizumab. No significant statistical differences (p > 0.05) were observed.

(a) Changes in the central retinal thickness during individual follow-up visits—comparison of treatment results for Aflibercept and Ranibizumab. The obtained decreases in retinal thickness did not differ significantly statistically between the two groups, (p > 0.05). (b) Average change in central retinal thickness after the first and second years of treatment—comparison of treatment results for Aflibercept and Ranibizumab. No significant statistical differences (p > 0.05) were observed.